COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein S1 D614G mutant (S1-D614G,C-HisTag)Cat No.: GMP-V-2019nCoV-Smu-001
|Package||Catalog No.||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Expression platform||2019-nCoV(SARS-CoV-2, SARS2-coronavirus)|
|Isotypes||Mamamlian (human cell)|
|Products description||Recombinant 2019-nCoV(SARS-CoV-2)e Spike Protein S1 domain with D614G mutant was expressed in mammanlian cell (human cells)expression system. The target gene encoding Gln14-Arg685(D614G) was expressed with HIS tag at the C-terminus.|
|Bioactivity validation|| ACE2 binding; |
Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
|Purity||Purity: ≥95% (SDS-PAGE)|
|Application||Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies.|
Immunogen in Elisa,lateral-flow tests,and other immunoassays;
The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
|predicted Molecular Mass||76kDa|
|Formulation||Lyophilized from sterile PBS, PH 7.4|
|Storage||Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.|
COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus) antigen:
Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-20 vaccines and therapeutic antibodies.
Validated in functional ELISA, other immunoassays, the antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
Spike Protein S1 D614G mutant (S1-D614G,C-HisTag).
The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. The D614G mutation in Spike S1 domain is proved to be a most important and popular mutant variant in Coronavirus SARS-CoV2.